Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics Inc. - Class A Ordinary Shares (APLM)
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics. “It’s our pleasure to welcome Matt to the Apollomics team. We expect his financial strategy and business development expertise from working with development and commercial stage public companies to be a critical asset as we execute our clinical, regulatory and commercialization plans,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “His appointment comes at a time of promising opportunity and growth for the company. We look forward to his contributions as we continue to execute on our vision of bringing vebreltinib and our other pipeline candidates through clinical trials and towards regulatory approval.” Dr. Plunkett added, “I am excited to
Show less
Read more
Impact Snapshot
Event Time:
APLM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLM alerts
High impacting Apollomics Inc. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APLM
News
- Apollomics Announces Private Placement Financing and Addition to Board of DirectorsGlobeNewswire
- Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneGlobeNewswire
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire
- Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire